Eli Lilly and Company (NYSE:LLY) has projected its full-year global revenue for 2024 to reach around $45 billion, marking a ...

The acquisition will expand Lilly's oncology pipeline with STX-478 ... or that the acquisition will yield commercially successful products. For further discussion of these and other risks and ...

Eli Lilly’s CEO Dave Ricks cited stocking levels and unexpected market dynamics in Q4 2024 in the GLP-1RA market.

president of Lilly Oncology. The agreement includes an upfront payment and subsequent payments upon achieving certain regulatory and sales milestones. As part of the deal, Scorpion will spin out a ...

US pharma major Eli Lilly is to buy the PI3Kα inhibitor program STX-478 from Scorpion Therapeutics, a private US biotech ...

executive vice president and president of Lilly Oncology, said in Monday’s announcement. Here are 71 Mass. life science firms presenting at J.P. Morgan As part of the deal, Scorpion is going to ...

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other ...

The acquisition will expand Lilly's oncology pipeline with STX-478, the differentiated and potentially best-in-class, mutant-selective PI3Kα inhibitor currently in a Phase 1/2 clinical trial STX ...

Eli Lilly and Company (NYSE: LLY) and Scorpion Therapeutics, Inc. ("Scorpion"), a private biotechnology company developing small molecule precision oncology therapies, today announced a definitive ...